IP-10 and type 1 diabetes: a question of time and location.
about
Inhibition of chemokine expression in rat inflamed paws by systemic use of the antihyperalgesic oxidized ATPSystemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CSpatiotemporal Dynamics of Insulitis in Human Type 1 DiabetesThe immunomodulatory role of syncytiotrophoblast microvesicles.Induction of an inflammatory loop by interleukin-1β and tumor necrosis factor-α involves NF-kB and STAT-1 in differentiated human neuroprogenitor cells.Quantification of chemokines by real-time reverse transcriptase PCR: applications in type 1 diabetes.Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction.CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?Allogeneic islet transplantation.Biomarkers for type 1 diabetes.Novel biomarkers in type 1 diabetes.Interleukin-21 is required for the development of type 1 diabetes in NOD mice.Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes.CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivationSmall molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model.Characteristics of rat CD4(+)CD25(+) T cells and their ability to prevent not only diabetes but also insulitis in an adoptive transfer model in BB ratsEnhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus
P2860
Q24815406-556FAACA-78E5-477E-8A88-BB2492B52F27Q28274298-599F4BBE-7EFF-436E-8B1C-8F6D6664BC79Q30833054-CC4F1B9F-B1D7-4B95-BD94-3C98C8F30A7FQ33919724-AB6DE3FE-DE61-4B63-B49C-65F9A8EA0DB3Q34903095-44BE96C6-0DB1-4A5D-91C8-8A5E2C95E87CQ36344113-97BBB1C8-D215-435C-AED7-527D4AC85882Q36560836-FFAC3240-BDB6-4669-8F42-66039B89AD82Q36676660-0404A247-22F1-4724-9881-621E328377D8Q36981652-8FCB8C24-8DEB-4991-B7E9-2CD8588F30C0Q37000150-B65A0ACE-76F8-4380-A254-0B436460391EQ37088197-E8C72F74-785D-40DF-9B59-35ECBFF2BD78Q37163453-C6427BCC-FA25-40F7-9B1C-2060A375C8B5Q37360404-69F1BCD4-BE0F-42C9-BB3B-6D6DA2855102Q42836727-A4610805-97B1-4E7E-87B9-2260C303697DQ45365916-62A5A214-E67F-49E1-AAAB-AB863D2F3A20Q56902065-D0E4F43E-DA8C-4DC9-8273-D739E4EA5CC1Q58620300-187EA654-4375-4F3F-97E4-E267C4B1CA54
P2860
IP-10 and type 1 diabetes: a question of time and location.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
IP-10 and type 1 diabetes: a question of time and location.
@ast
IP-10 and type 1 diabetes: a question of time and location.
@en
type
label
IP-10 and type 1 diabetes: a question of time and location.
@ast
IP-10 and type 1 diabetes: a question of time and location.
@en
prefLabel
IP-10 and type 1 diabetes: a question of time and location.
@ast
IP-10 and type 1 diabetes: a question of time and location.
@en
P2860
P1433
P1476
IP-10 and type 1 diabetes: a question of time and location
@en
P2093
Matthias G von Herrath
P2860
P304
P356
10.1080/08916930410001713124
P50
P577
2004-06-01T00:00:00Z